Evidence map›Paper›PMID 41254740›Full record

ArticleBMC pharmacology & toxicology2025

Revised therapeutic window for vancomycin in pediatric patients: evidence from a retrospective therapeutic drug monitoring study.

Tao Zhang, Jingjing Yi, Hua Cheng, Xinyan Han, Yan Wang, Jiao Xie, Qianting Yang, Sasa Hu, Yalin Dong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tao ZhangKey Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, China.
Jingjing YiDepartment of Neurology, The Third Affiliated Hospital of Xi'an Medical University, Xi'an, China.
Hua ChengDepartment of Pharmacy, The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an, China.
Xinyan HanKey Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, China.
Yan WangDepartment of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Jiao XieDepartment of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Qianting YangDepartment of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Sasa HuDepartment of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yalin DongDepartment of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. dongyalin@mail.xjtu.edu.cn.

Funding

National Science Fund for Distinguished Young Scholars 82404762
6 · The paper itself

Abstract

objectiveMethicillin-resistant Staphylococcus aureus (MRSA) infections among children are escalating annually. Vancomycin serves as the frontline therapeutic agent against MRSA infections. However, determining the therapeutic window that maximizes efficacy while minimizing the risk of toxicity for vancomycin in pediatric patients remains a challenge. This study aimed to explore a therapeutic window for vancomycin in pediatric patients.

methodsThis retrospective study collected data from hospitalized children aged 1 month to 18 years, who underwent routine therapeutic drug monitoring for vancomycin. We analyzed the distribution patterns of vancomycin concentrations in these patients. Factors influencing clinical outcomes and adverse reaction (nephrotoxicity) were investigated. ROC analysis was used to establish the therapeutic window for vancomycin in pediatric patients.

resultsA comprehensive dataset encompassing 183 pediatric patients with 330 samples was analyzed. The mean trough concentration (C

conclusionBased on our findings, we suggest a potential therapeutic window of 5.9-14.8 mg/L for vancomycin in pediatric patients, which may help optimize treatment efficacy and reduce toxicity. Further prospective studies are warranted to validate this range.

Indexed as

Anti-Bacterial AgentsStaphylococcal InfectionsVancomycinAdolescentChildChild, PreschoolDrug MonitoringFemaleHumansInfantMaleMethicillin-Resistant Staphylococcus aureusRetrospective StudiesAnti-Bacterial AgentsVancomycinPediatricsPharmacodynamicsTherapeutic drug monitoringTherapeutic windowVancomycin

Identifiers

PMID41254740
PMCPMC12625610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.